<DOC>
	<DOC>NCT01232296</DOC>
	<brief_summary>The purpose of this open-label, randomized, phase II study is to compare the safety and efficacy of dovitinib versus sorafenib as first-line treatment in adult patients with advanced Hepatocellular Carcinoma (HCC). This trial will be opened in countries of the Asia-Pacific region.</brief_summary>
	<brief_title>A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Diagnosis of advanced Hepatocellular Carcinoma (HCC) according to the AASLD Guidelines Advance HCC Stage B and C according to BCLC staging classification Child Pugh A At least one measurable lesion as assessed by CT or MRI ECOG PS of 0 or 1 Adequate bone marrow, liver, and renal function Prior systemic therapy for HCC Brain metastases Active bleeding (including variceal bleeding as the result of esophageal varices) Patients who have received a liver transplant or are awaiting an immediate transplant Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>HCC</keyword>
	<keyword>Liver cancer</keyword>
	<keyword>Child Pugh A</keyword>
	<keyword>HCC Stage C</keyword>
</DOC>